Clinical Study on the Treatment of Senile Alzheimer’s Dementia with Sodium Oligomannate Combined with Memantine Hydrochloride

Objective: To analyze the clinical effects of sodium oligomannate combined with memantine hydrochloride in the treatment of senile Alzheimer’s dementia. Methods: Sixty-eight cases of Alzheimer’s dementia treated at the Second People’s Hospital of Fujian University of Traditional Chinese Medicine from March 2020 to March 2022 were selected as the study subjects. The patients were divided into two groups based on different treatment methods: the control group (treated with memantine hydrochloride, 34 cases) and the treatment group (treated with sodium oligomannate + memantine hydrochloride, 34 cases). Cognitive function, activities of daily living, neurotransmitters, serum intestinal flora metabolic markers, inflammatory factors, neurotrophic factors, and adverse reactions were compared between the two groups. Results: The treatment group showed better cognitive function, quality of life scores, and levels of relevant metabolic markers in the body compared to the control group, with statistically significant differences (P < 0.05). The incidence of adverse reactions between the two groups (treatment group: 2%; control group: 4%) was not statistically significant (χ² = 0.731, P = 0.393). Conclusion: Sodium oligomannate combined with memantine hydrochloride has better efficacy than the control group for treating senile Alzheimer’s dementia. It significantly improves and restores cognitive function and daily living abilities, benefits neurotransmitter secretion and internal regulation, upregulates the expression of neurotrophic factors, and has fewer adverse reactions, making it a treatment worthy of further clinical promotion and application.